An in vivo method for determining cancer immunotherapy induced cytokine release syndrome utilizing PBMC humanized mice

被引：0
|
作者：
Ye, Chunting [1 ]
Cheng, Mingshan [1 ]
Brehm, Michael [2 ]
Greiner, Dale [2 ]
Shultz, Leonard [3 ]
Keck, James G. [1 ]
机构：
[1] Jackson Lab, Sacramento, CA USA
[2] Univ Massachusetts, Sch Med, Worcester, MA USA
[3] Jackson Lab, 600 Main St, Bar Harbor, ME 04609 USA
来源：
CANCER RESEARCH | 2019年 / 79卷 / 13期
关键词：
D O I：
10.1158/1538-7445.SABCS18-4990
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4990
引用
收藏
页数：2
相关论文
共 43 条
  • [1] An in vivo PBMC humanized mouse model for determining checkpoint and bispecific antibody treatment related cytokine release syndrome
    Ye, Chunting
    Cheng, Mingshan
    Brehm, Michael
    Greiner, Dale
    Shultz, Leonard
    Keck, James
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [2] A rapid, sensitive, and reproducible in vivo PBMC humanized murine model for determining therapeutic-related cytokine release syndrome
    Ye, Chunting
    Yang, Hongyuan
    Cheng, Mingshan
    Shultz, Leonard D.
    Greiner, Dale L.
    Brehm, Michael A.
    Keck, James G.
    FASEB JOURNAL, 2020, 34 (09): : 12963 - 12975
  • [3] PBMC-humanized mouse model for the assessment of cytokine release syndrome caused by checkpoint and bispecific immunotherapy
    Cai, Danying
    Jiao, Jing
    Ye, Chunting
    Yang, Hongyuan
    Cheng, Mingshan
    Brehm, Michael A.
    Greiner, Dale L.
    Shultz, Leonard D.
    Keck, James G.
    CANCER RESEARCH, 2020, 80 (16)
  • [4] Increased sensitivity for detecting cytokine release syndrome with cancer immunotherapy using a PBMC humanized NSG-SGM3 mouse model
    Ye, Chunting
    Brehm, Michael
    Cheng, Mingshan
    Shultz, Leonard
    Greiner, Dale
    Keck, James
    CANCER RESEARCH, 2019, 79 (13)
  • [5] Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy
    Morris, Emma C.
    Neelapu, Sattva S.
    Giavridis, Theodoros
    Sadelain, Michel
    NATURE REVIEWS IMMUNOLOGY, 2022, 22 (02) : 85 - 96
  • [6] Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy
    Emma C. Morris
    Sattva S. Neelapu
    Theodoros Giavridis
    Michel Sadelain
    Nature Reviews Immunology, 2022, 22 : 85 - 96
  • [7] An in vivo humanized mouse model for determining donor-dependent cytokine release syndrome in response to checkpoint and bispecific antibody therapy
    Draheim, Kyle M.
    Yang, Jiwon
    Jiao, Jing
    Cheng, Mingshan
    Keck, James G.
    JOURNAL OF IMMUNOLOGY, 2020, 204 (01):
  • [8] Editorial: Understanding the Cytokine Release Syndrome: Toward Improving Cancer Immunotherapy
    Martin-Antonio, Beatriz
    FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [9] TGN1412 induces dose and time dependent human cytokines in a humanized PBMC mouse model for cytokine release syndrome
    Yang, Hongyuan
    Jiao, Jing
    Cai, Danying
    Cheng, Mingshan
    Brehm, Michael
    Grainer, Dale
    Shultz, Leonard
    Keck, James
    CANCER RESEARCH, 2020, 80 (16)
  • [10] Targeting the A3 adenosine receptor to treat cytokine release syndrome in cancer immunotherapy
    Cohen, Shira
    Fishman, Pnina
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2019, 13 : 491 - 497
12345